Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07296094 · ClinicalTrials.gov registry record · Phase 2
Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder
A Phase 2 study, sponsored by Brigham and Women's Hospital.
- Not yet
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT07296094 is a Phase 2 study that has not yet begun recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 36 participants.
The verdict
NCT07296094, a Phase 2 study, has not yet begun recruiting, sponsored by Brigham and Women's Hospital.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
This study aims to determine the safety and preliminary efficacy of psilocybin-assisted psychotherapy in improving alcohol-related outcomes among adults with severe alcohol use disorder in a a double-blind, dose-comparison concurrent control, randomized trial. Participants will undergo structured psychotherapy and will be randomized to two psilocybin sessions to receive either a full dose (30mg or 40mg) or low dose (10mg or 15mg).
Interventions
- DRUG Psilocybin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2026-06-15 |
| Est. Completion | 2030-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07296094
The ClinicalTrials.gov registry entry for NCT07296094 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Psilocybin is the first listed.
NCT07296094 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07296094 about?
NCT07296094 is a clinical study titled "Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder". This study aims to determine the safety and preliminary efficacy of psilocybin-assisted psychotherapy in improving alcohol-related outcomes among adults with severe alcohol use disorder in a a double-blind, dose-comparison concurrent control, randomized trial. Participants will undergo structured ps...
What is the current status of trial NCT07296094?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2026-06-15. Estimated completion is 2030-02.
What interventions are being tested in trial NCT07296094?
The interventions under investigation include: Psilocybin (DRUG).
Who is sponsoring clinical trial NCT07296094?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.